Randomized, Double-blind, Placebo-controlled Phase 1b Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects
Status:
Recruiting
Trial end date:
2023-09-21
Target enrollment:
Participant gender:
Summary
This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and
pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV).
This study includes 3 planned cohorts. Participants will receive multiple-ascending doses of
GSBR-1290 or Placebo from Day 1 to Day 28